Integral Diagnostics Ltd. (IDX) AI Stock Analysis

• Market Cap: AU$1.03B
• Dividend Yield: 2.16%
• Average Volume (3M): 1.31M
• Price to Earnings (P/E): 114.0
• Beta (1Y): 0.10
• Revenue Growth: 7.83%
• EPS Growth: N/A
• Country: AU
• Employees: 1,977
• Sector: Healthcare
• Sector Strength: 40
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.04
• Shares Outstanding: 372,429,530
• 10 Day Avg. Volume: 694,603
• 30 Day Avg. Volume: 1,308,919
• PEG Ratio: 1.04
• Price to Book (P/B): 0.93
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 28.34
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$3.43
• Price Target Upside: 27.99% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 53 Neutral
• Price Target: AU$2.50 ▼(-6.72%Downside)

The overall stock score reflects a mixed financial performance with robust revenue growth and cash management but significant profitability challenges. Technical indicators are neutral, pointing to mild momentum without strong buying or selling signals. The high P/E ratio highlights valuation concerns, suggesting the stock may be overvalued, which impacts the overall attractiveness.

Integral Diagnostics Ltd. Business Overview & Revenue Model

Company Description

Integral Diagnostics Ltd. (IDX) is a leading provider of diagnostic imaging services in Australia and New Zealand. The company operates within the healthcare sector, focusing on the delivery of high-quality radiology services, including X-ray, ultrasound, CT, MRI, and nuclear medicine. With a network of clinics and partnerships with hospitals and medical practitioners, IDX is committed to providing accurate and timely diagnostic imaging to aid in the effective diagnosis and treatment of patients.

How the Company Makes Money

Integral Diagnostics Ltd. makes money primarily by offering a comprehensive range of diagnostic imaging services. Revenue is generated through the fees charged for imaging services, which are typically paid by patients, private health insurance, or government healthcare programs. The company's key revenue streams include direct payments from patients and reimbursements from health insurance providers and government agencies. Significant partnerships with hospitals and healthcare providers enhance its service offerings and accessibility, contributing to its earnings. Additionally, IDX may leverage technology and innovation to streamline operations and improve service delivery, further bolstering its financial performance.

Integral Diagnostics Ltd. Financial Statement Overview

Summary

Integral Diagnostics Ltd. demonstrates robust revenue growth and efficient cash management. However, significant challenges are evident in profitability, as seen in negative net income and deteriorating EBIT margins. The high leverage and negative return on equity indicate financial risks. While operational cash flow remains strong, the overall financial health is mixed, with strengths in revenue growth and cash management but weaknesses in profitability and leverage.

Income Statement

The company shows mixed results in its income statement. Gross profit margin is high at 95.12%, indicating effective cost management relative to revenue. However, the net profit margin is negative due to a net loss, which is a significant concern. Revenue growth is strong at 6.72% year-over-year, demonstrating a positive trend in sales. However, EBIT and EBITDA margins have declined sharply, reflecting operational challenges.

Balance Sheet

The balance sheet presents a stable financial position with an equity ratio of 40.54%, indicating a solid equity base. However, the debt-to-equity ratio is high at 1.19, pointing to significant leverage that could pose risks in challenging economic conditions. Return on Equity has turned negative due to the net loss, highlighting profitability issues.

Cash Flow

The cash flow statement reveals steady operational cash flows with an operating cash flow to net income ratio of -1.09, indicating strong cash generation relative to net income despite losses. Free cash flow growth is significant at 54.21%, showcasing effective cash management, but free cash flow to net income ratio is negative, underscoring profitability concerns.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	469.70M	440.10M	358.74M	348.81M	274.08M
Gross Profit	446.78M	97.76M	83.84M	92.19M	72.06M
EBITDA	12.33M	92.74M	69.90M	88.94M	69.50M
Net Income	-60.70M	25.04M	14.60M	31.27M	23.03M
Balance Sheet
Total Assets	744.28M	839.01M	783.01M	654.90M	586.91M
Cash, Cash Equivalents and Short-Term Investments	42.44M	33.85M	123.19M	62.20M	57.97M
Total Debt	357.80M	365.08M	340.99M	308.36M	277.85M
Total Liabilities	442.57M	465.96M	435.77M	400.16M	358.58M
Stockholders Equity	301.71M	373.05M	347.24M	254.74M	228.33M
Cash Flow
Free Cash Flow	42.28M	27.42M	9.33M	49.30M	28.37M
Operating Cash Flow	66.16M	71.42M	37.10M	69.57M	54.25M
Investing Cash Flow	-27.90M	-128.96M	-55.69M	-56.66M	-93.53M
Financing Cash Flow	-29.45M	-31.85M	81.13M	-7.83M	75.40M

Integral Diagnostics Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.68
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IDX, the sentiment is Positive. The current price of 2.68 is above the 20-day moving average (MA) of 2.59, above the 50-day MA of 2.46, and above the 200-day MA of 2.66, indicating a bullish trend. The MACD of 0.08 indicates Negative momentum. The RSI at 64.34 is Neutral, neither overbought nor oversold. The STOCH value of 82.01 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:IDX.

Integral Diagnostics Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SHL	73 Outperform	AU$13.82B	24.55	6.86%	3.83%	10.15%	6.20%
ACL	69 Neutral	AU$553.82M	18.32	18.39%	4.43%	7.80%	99.87%
Sector *	60 Neutral	HK$16.84B	5.17	-7.44%	2.89%	11.55%	-28.15%
MVF	55 Neutral	AU$300.02M	―	-0.87%	6.62%	14.24%	-109.59%
IDX	53 Neutral	AU$1.03B	113.99	1.14%	2.16%	7.83%	―
HLS	46 Neutral	€559.12M	―	-4.46%	―	-7.82%	98.08%
GSS	45 Neutral	AU$81.77M	―	-47.52%	―	44.61%	16.40%

Integral Diagnostics Ltd. Corporate Events

Integral Diagnostics to Host FY25 Results Conference Call

Integral Diagnostics Limited announced it will hold a group investor conference call on August 26, 2025, following the release of its FY25 results. This event is significant for stakeholders as it provides insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and operations.

The most recent analyst rating on (AU:IDX) stock is a Buy with a A$3.00 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.

Integral Diagnostics Faces Legal Claim Over Earn-Out Dispute

Integral Diagnostics Ltd. has been served with a legal claim by the Vendors of the Imaging Queensland business, which it acquired in 2019. The Vendors are seeking damages related to an earn-out valuation dispute, which was previously determined by an independent expert to be $2.2 million. Despite efforts by Integral to resolve the issue based on this valuation, the Vendors have initiated legal proceedings. Integral plans to defend itself in this litigation, which could have implications for its financial provisioning and stakeholder relations.

The most recent analyst rating on (AU:IDX) stock is a Buy with a A$3.00 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.

Integral Diagnostics CEO Announces Retirement, Initiates Leadership Transition

Integral Diagnostics (IDX) announced the upcoming retirement of its Managing Director and CEO, Dr. Ian Kadish, effective at the end of FY26. Dr. Kadish has significantly contributed to the company’s growth, transforming it into the second largest radiology provider in Australia and a notable presence in New Zealand. The company is conducting an international search for his successor, aiming for a seamless transition to maintain service standards and capitalize on recent synergies from its merger with Capitol Health.

The most recent analyst rating on (AU:IDX) stock is a Buy with a A$3.50 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.

Integral Diagnostics to Present at 2025 Macquarie Australia Conference

Integral Diagnostics announced its participation in the 2025 Macquarie Australia Conference, where it will present its latest developments. This engagement underscores IDX’s commitment to maintaining its leadership position in the medical imaging industry and highlights its ongoing efforts to enhance service quality and patient care.

Challenger Limited Ceases to be Substantial Holder in Integral Diagnostics

Challenger Limited has announced that it and its associated entities have ceased to be substantial holders in Integral Diagnostics Limited. This change in holdings may impact Integral Diagnostics’ shareholder composition and influence its market position, as substantial holders often have significant voting power and influence over company decisions.